John Tomich wears many hats at Kansas State University. As a
biochemistry faculty member he conducts NIH funded research
on synthetic peptides with interesting activities. His primary
interest is in the area of channel forming peptides. His lab
has developed more than 200 sequences that showed varied ion
transport activity in synthetic membranes as well as cultured
epithelial cells and animals. One set of peptide shows promise
in allowing the selective transport of chloride ions across
cells. These peptides show promise in restoring the chloride
imbalance seen in patients that suffer cystic fibrosis. Another
set of peptides temporarily alters the barrier function of epithelial
cells. These sequences are currently being investigated as possible
transport activators in epithelium. Pretreatment of cells with
the peptide facilitates the transport (uptake) of drugs or helpful
molecules that are normally excluded.
As director of the Biotechnology Core Lab he oversees synthetic and analytic services offered to researchers around the world. The lab specializes in the chemical synthesis of peptides, mass spectrometry, protein sequencing, plasmon resonance and solution NMR structure analysis of membrane spanning peptides.
Tomich is also one of the founders of a small biotech company, Nacelle Therapeutics, Inc. He is currently chief technical officer. This company was founded to help commercialize some of the peptides developed at Kansas State University.
Tomich received his bachelor's degree in biology with a minor in chemistry from the University of Connecticut in 1974 and his master's degree in biochemistry from Purdue University in 1974. He went on to receive his doctorate in chemistry from the University of Waterloo in Ontario, Canada, in 1980.
He is member of Sigma Xi, the Biophysical Society, the Association for Biomolecular Resource Facilities, the American Peptide Society and the Federation for American Scientists for Experimental Biology.
Tomich can be reached at 785-532-5956 or by e-mail at jtomich@k-state.edu.